# Thymosin Alpha-1: Research Overview — Lazarus Research Peptides > A literature summary of Thymosin Alpha-1 (Thymalfasin), the lead Immune & Thymic research peptide: TLR-mediated immunomodulation, clinical sepsis trials, COVID-19 evidence, and regulatory standing. A 28-amino-acid thymic immunomodulator approved in more than 35 countries — and recently tested in the largest, most rigorous sepsis RCT to date, which came back negative. ## The short version Thymosin Alpha-1 is a short protein — 28 amino acids — that the thymus gland produces naturally as a fragment of a larger precursor called prothymosin alpha. The synthetic drug version, called thymalfasin, is sequence-identical. Researchers study it because it appears to act at the junction of the innate and adaptive immune systems: it matures dendritic cells, promotes T-cell differentiation, and can shift immune responses toward a more active Th1 profile [6][7]. The clinical record is unusually broad. Thymalfasin is approved in more than 35 countries for indications including chronic hepatitis B and C and immune reconstitution in cancer and HIV, and it has been studied in sepsis, COVID-19, and oncology adjuvancy [2]. That record deserves one honest correction: the largest and most rigorous sepsis trial — 1,106 adults in a phase-3 double-blind RCT — found no significant mortality benefit [1]. This page summarizes what was studied; it does not recommend any dose or use. ## What it is Thymosin Alpha-1 is a 28-amino-acid, N-terminally acetylated polypeptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn. It is highly acidic, carries no aromatic residues, and forms no disulfide bonds. N-terminal acetylation is essential for biological activity. It is cleaved in vivo from the 113-amino-acid precursor prothymosin alpha. The synthetic drug thymalfasin is chemically identical to the natural peptide and was isolated and characterized from calf thymus in 1977 [7]. It is distinct from Thymulin (a 9-amino-acid zinc-dependent thymic hormone) and from thymosin beta-4 or its fragment TB-500 (an actin-binding peptide with no relation to thymosin alpha-1). These are three separate molecules with separate mechanisms. ## How it works Thymosin Alpha-1 operates at the innate-adaptive immune interface. It signals through Toll-like receptors — notably TLR2 and TLR9 — on dendritic cells and monocytes, promoting their maturation, interleukin-12 production, and antigen presentation. This in turn drives T-cell maturation and Th1 polarization, the arm of immunity most relevant to clearing intracellular pathogens [6]. Simultaneously, Thymosin Alpha-1 engages the IDO (indoleamine 2,3-dioxygenase) / tryptophan-catabolism pathway, which generates regulatory T cells and interleukin-10. This gives it a dual character: it restores effector immunity in immunosuppressed states while also modulating hyperinflammation [6]. In a retrospective COVID-19 cohort, this profile was linked to reversal of T-cell exhaustion — reduced PD-1 and Tim-3 expression on CD8+ T cells — in patients with severe lymphocytopenia [3]. ## What the research shows *Isolation and structure.* Thymosin alpha-1 was purified from calf thymus fraction 5 in 1977; Goldstein and colleagues determined its complete 28-residue sequence and established its immunological activity [7]. *Sepsis — the null large trial.* The phase-3 TESTS trial enrolled 1,106 adults with sepsis across 22 centres in a double-blind, randomised, placebo-controlled design. Twenty-eight-day all-cause mortality was 23.4% in the thymosin alpha-1 group versus 24.1% in placebo: hazard ratio 0.99 (95% CI 0.77–1.27), P=0.93 [1]. *Sepsis — an earlier positive signal.* The multicentre ETASS trial of 361 severe-sepsis patients found 28-day mortality of 26.0% (Tα1) versus 35.0% (control), an absolute reduction of ~9 percentage points that did not reach conventional significance (P=0.062; log-rank P=0.049) and was accompanied by improved HLA-DR expression on monocytes [5]. *COVID-19.* In a retrospective review of 76 patients with severe COVID-19, thymosin alpha-1 was associated with significantly reduced mortality (11.1% vs 30.0%, P=0.044), increased T-cell numbers in lymphocytopenic patients, and reversal of CD8+ T-cell exhaustion markers [3]. *Cancer adjuvancy.* A review of oncology data positions Thymosin Alpha-1 as an immunostimulatory adjuvant used in combination with chemotherapy and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer, potentially converting immunologically "cold" tumours and mitigating checkpoint-inhibitor toxicity through mucosal homeostasis [4]. *Mechanism.* The 2006 mechanistic study confirmed TLR9-dependent IDO activation on dendritic cells, establishing the dual Th1-priming and regulatory framework [6]. *Safety profile.* A comprehensive review of four decades of clinical literature establishes a benign safety profile. The most common adverse effects are mild local injection-site irritation; the standard single subcutaneous dose ranges from 0.8 to 6.4 mg; thymalfasin is approved in more than 35 countries [2]. ## Reported effects, cautions & safety Community-reported signals for Thymosin Alpha-1 (anecdotal, not clinical evidence): - Fewer or shorter colds and seasonal infections over a course — the most commonly reported anecdotal benefit, self-reported impression rather than measured immunity. - Faster recovery from being run-down or sick — people describe bouncing back sooner, though no controlled outcome is being tracked. - A general sense of immune resilience — vague but positive; highly subjective and prone to expectation effects. - Steadier energy during recovery from chronic illness — reported by some dealing with post-viral fatigue; not a substitute for clinical evaluation. - Generally well tolerated — consistent with its benign documented safety profile. - Injection-site redness, itching, or stinging — the single most common adverse complaint; typically brief and self-limiting. - Occasional short-lived flu-like or achy feeling — transient, early in a course, uncommon. - Mild headache or tiredness around dosing days — inconsistent reports. - "Didn't notice anything" — a frequent report; the effects are biochemical, not perceptible. - Tempered expectations after the null sepsis headlines — more informed users cite the 2025 TESTS result and caution others not to assume dramatic benefits. Literature-grounded cautions: - *Theoretical autoimmune caution.* An immunostimulant that promotes Th1 polarization and cytotoxic T-cell activity is a theoretical concern in established autoimmune conditions, even though the IDO regulatory arm may counterbalance this [6]. - *Theoretical transplant caution.* T-cell maturation and reversal of T-cell exhaustion could work against deliberate immunosuppression in solid-organ transplant recipients [6]. - *Efficacy expectations.* The largest and most rigorous sepsis trial was null (HR 0.99, P=0.93); earlier positive signals were smaller and less rigorous [1]. - *Limited pregnancy and lactation data.* No dedicated pregnancy or lactation safety studies; the literature does not characterize fetal or infant risk [2]. - *US non-approval and research-grade quality.* Thymosin Alpha-1 is not FDA-approved for marketing in the US; research-grade material sits outside the regulated drug-quality chain, so purity, content, and sterility are not guaranteed [2]. ## Where it fits in immune research Among the three peptides on this desk, Thymosin Alpha-1 is the lead and the most clinically documented. Its story spans four decades: from original isolation in bovine thymus [7], through international drug approvals in dozens of countries [2], to a large rigorous null result in sepsis [1]. Its dual immunomodulatory mechanism — Th1 priming and regulatory modulation — is among the best characterised of any thymic peptide. Compare it with [Thymulin](/thymulin), which is hormonal and zinc-dependent, and [KPV](/kpv), which quiets inflammation at the local tissue level. See the [comparison page](/compare) for the side-by-side. ![Thymosin Alpha-1 research illustration](/images/thymosin-alpha-1.webp) --- A literature digest of peer-reviewed immune and thymic peptide research — citations in hand, no products on offer.